Skip to main content
OxyPrem AG logo

OxyPrem AG

Zürich, Canton of Zürich, SwitzerlandSee on the mapFounded 2018

  • Seed

OxyPrem AG is a Swiss medical device manufacturer developing non-invasive systems that monitor oxygenation in human tissue in real time. Its near-infrared sensors are designed to give medical teams accurate insights for clinical decisions, particularly when caring for vulnerable newborns and other high-risk patients.

Raised
$25.8M
Aug 2019
Seed
Investors
4
Founded
2018
Employees
11–50

reccy insights

Recent highlights

OxyPrem’s latest recorded financing was an equity crowdfunding round announced on Aug 30, 2024, with $3,228,859 raised and Capital Cell identified as a lead investor. The company’s financial overview lists a valuation of 17 million EUR on that same date. Its product focus is continuous, non-invasive monitoring of tissue oxygenation in vulnerable newborns, using near-infrared light to provide clinicians with real-time information about brain oxygen levels. The NOAH Tissue Oximeter System has obtained CE marking, and the company also identifies the OxyPrem 1.4 tissue oximeter as a product. Wolf Martin and Alexander Nitsch are listed as founders. The available details point to product development and financing as the clearest documented milestones, rather than a sequence of publicly announced commercial launches or organizational changes.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes OxyPrem AG distinct

  1. 01Provides continuous, real-time tissue oxygenation measurements using harmless, non-invasive near-infrared light.
  2. 02Focuses on monitoring high-risk and premature newborns.
  3. 03Combines reusable sensors with advanced algorithms, including self-calibration.
  4. 04The NOAH Tissue Oximeter System has obtained CE marking.

Technology & products2

  • OxyPrem 1.4 tissue oximeter

    A tissue oximeter for non-invasive monitoring of tissue oxygenation.

  • NOAH Tissue Oximeter System

    A CE-marked system for continuous tissue oxygenation monitoring, designed for clinical use with high-risk newborns.

  • OxyPrem 1.4 tissue oximeter
  • NOAH Tissue Oximeter System
  • Non-invasive near-infrared tissue oxygenation sensors
  • Advanced self-calibration algorithms

Research roots2

Labs and research groups this company came from or works with.

  • University Hospital ZurichZurich, Switzerland · No page yet
    Spin-out
  • University of ZurichZurich, Switzerland · No page yet
    Spin-out
Academic data: Carter Sciences

Recent updates3

  • Aug 2026Product launch

    NOAH Tissue Oximeter System has obtained CE marking

    extern.cloud.oxyprem.com
  • Nov 2025Award

    Top 12: Health Techpreneur 2025

    oxyprem.com
  • May 2025Award

    Finalist at the Swissnex Internationalization Award 2025

    oxyprem.com

Funding

$25.8M disclosed
Latest valuation 17 million EUR4 investors

Investors4

Also backed by
  • Capital Cell

About OxyPrem AG

Products
OxyPrem 1.4 tissue oximeter, NOAH Tissue Oximeter System
Leadership
Wolf MartinAlexander Nitsch
Focus areas
Medical devices, neonatal care, patient monitoring, tissue oximetry, near-infrared technology, diagnostics, digital health
Headquarters
Zürich, Canton of Zürich, Switzerland
Founded
2018
Employees
11–50
Status
Active · private